These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 23703021

  • 1. Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.
    Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.
    J Pharm Sci; 2013 Sep; 102(9):3145-60. PubMed ID: 23703021
    [Abstract] [Full Text] [Related]

  • 2. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
    Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.
    J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
    [Abstract] [Full Text] [Related]

  • 3. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R, Schreurs M, Benne MS, Huisman MT, Russel FG.
    Eur J Pharm Sci; 2013 Aug 16; 49(5):819-28. PubMed ID: 23806476
    [Abstract] [Full Text] [Related]

  • 4. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ, Sandmann S, Engel K, Radtke M.
    Drug Metab Dispos; 2010 Aug 16; 38(8):1341-6. PubMed ID: 20413726
    [Abstract] [Full Text] [Related]

  • 5. Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil.
    Estudante M, Maya M, Morais JG, Soveral G, Benet LZ.
    Mol Pharm; 2013 Nov 04; 10(11):4038-45. PubMed ID: 24044638
    [Abstract] [Full Text] [Related]

  • 6. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A.
    Curr Drug Metab; 2010 Nov 04; 11(9):716-29. PubMed ID: 21189140
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
    Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G, Rostami-Hodjegan A.
    Drug Metab Dispos; 2016 Mar 04; 44(3):476-80. PubMed ID: 26842595
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y, Hu ZY.
    Br J Pharmacol; 2014 Feb 04; 171(4):1043-53. PubMed ID: 24283665
    [Abstract] [Full Text] [Related]

  • 13. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
    Oga EF, Sekine S, Shitara Y, Horie T.
    J Ethnopharmacol; 2012 Dec 18; 144(3):612-7. PubMed ID: 23064285
    [Abstract] [Full Text] [Related]

  • 14. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
    Martin P, Gillen M, Millson D, Oliver S, Brealey C, Elsby R, Baluom M, Lau D, Mant T.
    Clin Ther; 2015 Dec 01; 37(12):2811-22. PubMed ID: 26514315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
    Kishimoto W, Ishiguro N, Ludwig-Schwellinger E, Ebner T, Schaefer O.
    Drug Metab Dispos; 2014 Feb 01; 42(2):257-63. PubMed ID: 24212378
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Modeling the kinetics of digoxin absorption: enhancement by P-glycoprotein inhibition.
    Weiss M, Sermsappasuk P, Siegmund W.
    J Clin Pharmacol; 2012 Mar 01; 52(3):381-7. PubMed ID: 21343347
    [Abstract] [Full Text] [Related]

  • 19. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
    Castagne V, Bonhomme-Faivre L, Urien S, Ben Reguiga M, Soursac M, Gimenez F, Farinotti R.
    Drug Metab Dispos; 2004 Feb 01; 32(2):168-71. PubMed ID: 14744937
    [Abstract] [Full Text] [Related]

  • 20. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.
    Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L.
    Clin Pharmacol Ther; 2003 Jan 01; 73(1):51-60. PubMed ID: 12545143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.